Pacritinib citrate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for pacritinib citrate and what is the scope of patent protection?
Pacritinib citrate
is the generic ingredient in one branded drug marketed by Cti Biopharma Corp and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Pacritinib citrate has seventy-seven patent family members in twenty-seven countries.
One supplier is listed for this compound.
Summary for pacritinib citrate
International Patents: | 77 |
US Patents: | 3 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 2 |
Patent Applications: | 4 |
DailyMed Link: | pacritinib citrate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for pacritinib citrate
Generic Entry Date for pacritinib citrate*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for pacritinib citrate
US Patents and Regulatory Information for pacritinib citrate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Cti Biopharma Corp | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712-001 | Feb 28, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for pacritinib citrate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2629455 | DERIVES DE PYRIMIDINE A LIAISON HETEROALKYLE (HETEROALKYL LINKED PYRIMIDINE DERIVATIVES) | ⤷ Try a Trial |
Taiwan | I525096 | ⤷ Try a Trial | |
Russian Federation | 2527970 | ЦИТРАТ 11-(2-ПИРРОЛИДИН-1-ИЛ-ЭТОКСИ)-14,19-ДИОКСА-5,7,26-ТРИАЗАТЕТРАЦИКЛО[19.3.1.1(2,6).1(8,12)]ГЕПТАКОЗА-1(25),2(26),3,5,8,10,12(27),16,21,23-ДЕКАЕНА (11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZATETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE) | ⤷ Try a Trial |
South Korea | 101568801 | ⤷ Try a Trial | |
Argentina | 074724 | SAL DE CITRATO 11-(2-PIRROLIDIN-1-IL-ETOXI)-14,19-DIOXA-5,7,26-TRIAZA-TETRACICLO (19.3.1.1(2,6).1(8,12) HEPTACOSA-1-(25),2(26),3,5,8,10,12 (27),16,21,23-DECAENO | ⤷ Try a Trial |
Hong Kong | 1123282 | 氧連接的嘧啶衍生物 (OXYGEN LINKED PYRIMIDINE DERIVATIVES) | ⤷ Try a Trial |
Taiwan | I506029 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |